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Abstract
Background and Aims: Mutations reducing the function of Nav1.7 sodium channels entail diminished pain perception and
olfactory acuity, suggesting a link between nociception and olfaction at ion channel level. We hypothesized that if such link
exists, it should work in both directions and gain-of-function Nav1.7 mutations known to be associated with increased pain
perception should also increase olfactory acuity.
Methods: SCN9A variants were assessed known to enhance pain perception and found more frequently in the average
population. Specifically, carriers of SCN9A variants rs41268673C.A (P610T; n=14) or rs6746030C.T (R1150W; n=21) were
compared with non-carriers (n=40). Olfactory function was quantified by assessing odor threshold, odor discrimination and
odor identification using an established olfactory test. Nociception was assessed by measuring pain thresholds to
experimental nociceptive stimuli (punctate and blunt mechanical pressure, heat and electrical stimuli).
Results: The number of carried alleles of the non-mutated SCN9A haplotype rs41268673C/rs6746030C was significantly
associated with the comparatively highest olfactory threshold (0 alleles: threshold at phenylethylethanol dilution step 12 of
16 (n=1), 1 allele: 10.662.6 (n=34), 2 alleles: 9.562.1 (n=40)). The same SCN9A haplotype determined the pain threshold to
blunt pressure stimuli (0 alleles: 21.1 N/m
2, 1 allele: 29.8610.4 N/m
2, 2 alleles: 33.5610.2 N/m
2).
Conclusions: The findings established a working link between nociception and olfaction via Nav1.7 in the gain-of-function
direction. Hence, together with the known reduced olfaction and pain in loss-of-function mutations, a bidirectional genetic
functional association between nociception and olfaction exists at Nav1.7 level.
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Introduction
Rare variants of voltage-gated sodium channels Nav1.7 [1]
coded by homozygous nonsense mutations in the SCN9A gene
result in truncated, non-functional sodium channels that produce
ion currents no greater than background [2]. Nav1.7 channels are
expressed on pain receptors and afferent nociceptive neurons
[3,4]. Thus these [2] and other loss-of-function variants cause a
complete [5,6] or a partial [7] insensitivity to pain. Due to its
important role in pain perception and because their expression is
restricted to peripheral sensory neurons [8], Nav1.7 channels are
presently reckoned as a promising target for the development of
new analgesics [9,10].
However, expression of Nav1.7 channels is not confined to
nociceptive neurons. They are also expressed on olfactory neurons
[11], where they have been shown to be the most predominant
sodium channel in rodents [12]. In the absence of functional
Nav1.7 channels, olfactory neurons continue to produce action
potentials after excitation by odors but fail to initiate synaptic
signaling [13]. Hence a common co-phenotype in patients
carrying loss-of-function variants of SCN9A is anosmia [2,5,6,13]
which continues to raise scientific interest in pain-focused reports
[14]. This suggests a link between nociception and olfaction at ion
channel level [15].
Based on the physiological function of Nav1.7, we hypothesized
that this link should work in both directions. That is, gain-of-
function SCN9A variants, causing severe pain attacks by enhancing
channel activation or impairing channel inactivation associated
with inherited primary erythromelalgia or the paroxysmal pain
syndrome [16–26], should also cause enhanced olfaction. To
prove the hypothesis, human carriers of more frequent SCN9A
variants, i.e., rs6746030C.T (R1150W) found at an allelic
frequency in caucasians of ,14%, and associated with decreased
heat thresholds [27], and rs41268673C.A (P610T), found at an
allelic frequency of ,4% and also modulating nociception [28],
were studied for their joint nociceptive and olfactory effects.
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Subjects and Design
The study followed the Declaration of Helsinki and was
approved by the Ethics Committee of the Goethe-University
Frankfurt am Main, Germany. Informed written consent from
each participating subject had been obtained. In general, data
storage and handling was performed in compliance with the data
protection act of the German federal state Hessen, i.e., Hessisches
Datenschutzgesetz (HDSG), and the German Federal Data
Protection Act, i.e., Bundesdatenschutzgesetz (BDSG). All partic-
ipants were of Caucasian ethnicity by self-assignment. Three
genotypic groups were enrolled, i.e. non-carriers of the minor
alleles of SCN9A rs41268673C.A (P610T) and rs6746030C.T
(R1150W), and carriers of either of the minor alleles. Power
calculations based on published data [29,30] had resulted in group
sizes of 10 to observe differences of 15% in nociceptive thresholds
[30] and of 16 to observe clinically relevant differences of 5.5
points [31] in an olfactory score, both at a power of 80% and an a
error of 5%. To further increase the power, the group size for wild
type subjects was roughly doubled to 40. The enrolled cohort
finally consisted of 29 healthy men and 46 women (age 20–43
years, mean 6 standard deviation 26.164.2 years) of whom 40
were wild type with respect to both SCN9A loci, 14 carried the
minor rs41268673A allele and 21 the minor rs6746030T allele.
The subjects actual health was assessed by medical history,
physical examination including vital signs, and routine clinical
laboratory test results.
Genotyping
Compared with the rare gain-of-function variants associated
with pathologically syndromes of exacerbated pain episodes, the
selected variants confer only moderate pain enhancing effects.
However, their frequency is high enough to allow for the present
controlled study investigating the link between enhanced nocicep-
tion and olfaction at Nav1.7 sodium channel level. The variant
rs6746030C.T causes an amino acid exchange from arginine to
tryptophan at position 1150 located in the intracellular loop
between transmembrane domains II and III of Nav1.7, a region of
the channel with unknown function. Thus, the exact mechanism of
the enhanced pain sensitivity is unclear. Electrophysiological
assessments showed a slightly lesser voltage-dependent slow
inactivation of Nav1.7 1150W (encoded by the minor A allele)
proposed to cause changes in the setting of the threshold and firing
frequency of nociceptive neurons and thus to render the neurons
more sensitive to painful stimuli [27]. Furthermore, Nav1.7
1150W produced hyperexcitability when expressed in rat dorsal
root ganglion neurons [22].The other variant, rs41268673C.A,
causes an amino acid exchange at position 610 from proline to
threonine, however, its molecular consequences are unknown yet.
DNA samples were available from 822 unrelated subjects of
Caucasian ethnicity (mostly medical students) who had consented
into genotyping. Ethics approval for genotyping had been
obtained. Genomic DNA was extracted from 200 ml blood using
the EZ1 DNA Blood 200 ml Kit on a BioRobot EZ1 Workstation
(Qiagen, Hilden, Germany). Genotyping for the functional
variants SCN9A rs41268673C.A and rs6746030C.T was done
from genomic DNA by means of Pyrosequencing
TM assays on a
PSQ 96 MA System (Qiagen, Hilden, Germany) using the
PyroMark Gold Q96 Reagents set (Qiagen, Hilden, Germany).
PCR reactions were performed in a 25 ml assay volume on a
Mastercycler ep gradient S instrument (Eppendorf, Hamburg,
Germany), using the HotStar plus Taq Polymerase system
(Qiagen, Hilden, Germany) and SNP-specific PCR primers (for
rs41268673 forward primer: 59-GCGACGCAGCAGTAACAT-
CAG-39 and reverse primer: 59-biotin- TGTAAAACGTCCT-
TACGCTGTCA-39; for rs6746030: forward primer: 59-
TTTGGTTGAGGGAGTATCACAGAA-39 and reverse primer:
59-biotin-TTGTAGCAGGTTTTCCTGATGTTC-39, respec-
tively). The PCR was done with an initial denaturation step for
5 min at 95uC, 45 cycles with a 30 second denaturation step at
95uC, an annealing step at primer-specific temperatures (56uC for
rs41268673C.A and 58uC for rs6746030C.T) for 30 s and an
elongation step at 72uC for 30 seconds, followed by a final
elongation step at 72uC for 5 min. The PCR products (25 ml) were
used in the Pyrosequencing analyses as previously described [32]
with the sequencing primers 59- CCAAGCCAGTAGGTCC-39
for rs41268673C.A and 59-CTTTCTTGTCAGGTTGTG-39
for rs6746030C.T, respectively. For both assays, three samples of
each genotype were selected, sequenced by conventional means
(LGC GmbH, Berlin, Germany) and used as positive controls
during Pyrosequencing
TM. Linkage disequilibrium (parameters D9
and r
2 [33,34]) between SNPs was analyzed using the Haploview
software [35]. Haplotypes were obtained in-silico using PHASE
software [36] after having established that the two SNPs were
located on the same haploblock according to the solid spine of LD
algorithm implemented in Haploview.
Assessment of Nociceptive and Olfactory Sensitivity
Olfactory testing. The olfactory test was based on felt-tip
pens that contained a solution of an odorant instead of liquid dye
(‘‘Sniffin’ Sticks’’: Burghart, Wedel, Germany [37]). The pen’s cap
was removed by the experimenter for approximately 3 s and the
pen’s tip was placed 1–2 cm in front of the nostrils, in the case of
triplet pen presentation at an interval of approximately 3 s. Three
main components of olfactory function were assessed birhinally.
Specifically, odor thresholds were obtained for the rose-like
odor phenylethylalcohol presented in 16 successive 1:2 dilution
steps starting from a 4% solution. Using a three-alternative forced-
choice task (3-AFC) and a staircase paradigm starting at low
phenylethylalcohol concentrations, one pen with the odorant and
two blanks were presented at each dilution step. Two successive
correct or one incorrect identification triggered the reversal of the
staircase. The odor threshold was the mean of the last four out of
seven staircase reversals (normal values .6 [29]).
Odor discrimination was determined with 16 triplets of
pens, two containing the same odorant and the third a different,
‘‘target’’ one (i.e., (target/non-target) butanol/2-phenyl ethanol,
isoamylacetate/anethole, anethole/eugenol, limonene/fenchone,
(-)carvone/(+)carvone, eugenol/cinnamon aldehyde, dihydroro-
senoxide/menthol, acetaldehyde/isoamylacetate, citronellal/linal-
ool, pridine/limonene, limonene/citronellal, eucalyptol/dipyridyl,
dipyridyl/cyclopentadecanoate, butanol/fenchone, octylacetate/
cinnamon aldehyde, carvone/acetaldehyde). The discrimination
performance was assessed employing a 3-AFC task (normal score
$11 correct discriminations).
Finally, odor identification was determined with 16 odors
(i.e., orange, leather, cinnamon, peppermint, banana, lemon,
liquorice, turpentine, garlic, coffee, apple, clove, pineapple, rose,
anise and fish) using a four-alternative forced-choice task with
presentation of a list of four descriptors for each pen (normal score:
$12 correct identifications).
The evaluation of olfactory performance followed the clinically
established procedure consisting of calculating a composite ‘‘TDI
score’’ (‘‘Threshold Discrimination Identification’’) as the sum of
the scores from the three subtests [38]. Pathologic olfactory
function is indicated by TDI #30.5, with the separation of
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#15.5 [29].
Experimental pain threshold testing. Heat pain thresh-
olds, as described previously [30], were obtained using a Thermal
Sensory Analyzer (Medoc Advanced Medical Systems Ltd., Ramat
Yishai, Israel). Heat stimuli (range 32–52.5uC) were applied with a
363c m
2 thermode placed on a skin area of the left or right
(randomized) volar forearm. Temperature was continuously
increased by 0.3uC/s starting at 32uC. The subject pressed a
button at the first sensation of pain, defined as the heat pain
threshold, which triggered cooling of the thermode by 10uC/s.
Heat stimuli were applied eight times at intervals of 25–35 s. The
median of last five responses was used as heat pain threshold
because in previous experiments a plateau was reached after the
first three measurements.
Cold pain thresholds were determined with the same
equipment as heat pain thresholds. Cold stimuli (range 32–0uC)
were applied with the 363c m
2 thermode placed on a skin area of
the volar forearm opposite to the side used for the determination of
the heat pain threshold. Temperature was continuously lowered
from 32uCt o0 uCb y1 uC/s. Since preliminary experiments had
not indicated any directed tendency of the first measurements,
cold pain thresholds were measured only five times and the
median of these measurements was submitted to the statistical
analysis.
Pain thresholds to electrical stimuli were obtained using a
constant current device (NeurometerH CPT, Neurotron Inc.,
Baltimore, MD) that delivered sine-wave stimuli at 5 Hz applied
via two gold electrodes placed on the medial and lateral side of the
mid-phalanx (middle finger of the right hand as default-testing
site). Their intensity was increased from 0 to 20 mA by 0.2 mA/s.
During the test, subjects kept a button continuously pressed until
they felt pain and interrupted the current by releasing the button.
The electrical current at which this occurred was defined as the
pain threshold. Measurements were repeated five times at intervals
of 30 s and the median was analyzed.
Pain thresholds to blunt pressure were obtained using a
pressure algometer with a circular and flat probe of 1 cm diameter
(Commander Algometer, JTECH Medical, Midvale, Utah). It was
placed perpendicularly onto the mid-phalanx of the right middle
finger. The pressure was increased at a rate of approximately 9 N/
cm
2 per second until the subject indicated pain. The increase in
pressure was controlled manually by the investigator and stopped
once the subject reported pain. The maximum pressure applied
was recorded automatically. The procedure was repeated five
times at intervals of 30 s. Mechanical pain threshold to blunt
pressure was the median of the five measurements.
Statistics
The hypothesis of the assessments was that SCN9A SNPs
previously associated with high pain due to sodium Nav1.7
hyperactivity are also associated with increased olfactory acuity.
Therefore, the analysis firstly aimed at identifying the SCN9A
variant that modulated an olfactory parameter by submitting each
olfactory parameter (odor threshold, discrimination, identification)
to multiple linear regression analysis (SPSS 21 for Linux, SPSS
Inc., Chicago, USA) with stepwise inclusion of SCN9A variants. As
the hypothesis was directed, i.e., higher sensitivity was the
expected effect of the variants [22], post-hoc tests were one-sided
using the Jonckheere–Terpstra trend test as a gene dose effect was
expected. The same test was applied subsequently to identify
whether the SCN9A variant identified as modulating olfaction also
modulated pain. The a-level was set at 0.05 and corrected for
multiple testing (Bonferroni) when indicated.
Results
In the random sample of 822 subjects screened for this study,
the observed minor allelic frequencies were 3.6% for variant
rs41268673C.A and 14% for rs6746030C.T; Hardy-Weinberg
equilibrium was preserved (x
2 test: p.0.05). Further analyses were
done in the study cohort of 75 subjects selected for SCN9A
genotypes. Linkage disequilibrium parameters between the two
SCN9A SNPs were D9=100 and of r
2=2 and both SNPs were
located together in a haploblock. Therefore, association analyses
focused on haplotypes. The non-mutated haplotype
rs41268673C/rs6746030C was found at an allelic frequency of
75.7% (and in the random sample of n=822 it had a frequency of
82.5%), the haplotype with major allele of the rs41268673 SNP
and variant (minor) allele of the rs6746030SNP, i.e.,
rs41268673C/rs6746030T, was found at an allelic frequency of
13.8%, and the haplotype with variant allele of the rs41268673
SNP and major allele of the rs6746030 SNP, i.e., rs41268673A/
rs6746030C, had an allelic frequency of 10.5%. A haplotype with
both minor alleles was not found.
None of the subjects reported any perception of pain or smell
sensitivities differing from the normal status. Most subjects (n=72)
were normosmic (TDI score $30.5 [29]). Among the three
hyposmic subjects (TDI of 28, 29 and 30, respectively), the wild
type haplotype rs41268673C/rs6746030C was carried in a total of
five copies. Multiple linear regression analysis of olfactory
parameters identified the SCN9A wild-type haplotype as the
genetic factor that statistically significantly influenced olfactory
thresholds (p=0.024). An increasing number of non-mutated
haplotype alleles was associated with a higher threshold, i.e., with
the detection limit of volatile phenylethylethanol at lower dilutions
(Figure 1). This was reflected in a statistically significant trend
(Jonckheeres trend test p=0.013 one-sided). The same wild-type
haplotype also modulated the pressure pain threshold (Jonckheeres
trend test p=0.033 one-sided). In addition, pressure pain
thresholds were significantly modulated by the rs41268673A/
rs6746030C haplotype (p=0.022) in the expected direction of
carriers having lower thresholds than wild-type subjects.
The remaining olfactory parameters and pain thresholds to heat
and punctate mechanical stimuli differed only insignificantly
between the identified haplotypes, but still observed variations
displayed a tendency in the hypothesized direction. Specifically,
the composite olfactory TDI scores dwindled with each additional
wild-type haplotype from a value of 40 in the carrier of zero wild-
type haplotypes (n=1), to 3763.4 in carriers of one wild-type
haplotype (n=34), to 35.463.2 in carriers of two wild-type
haplotypes (n=40). Likewise, the heat and cold pain threshold
tended in the direction expected from animal experiments [39],
i.e., the heat pain threshold was lower while the cold pain
threshold was higher in carriers of one wild-type haplotype
(45.563.3uC and 13.169.6, respectively; n=34) compared to
carriers of two wild-type haplotypes (46.562.2uC and 9.969.3uC,
respectively; n=40).
Discussion
The study hypothesis that SCN9A gain-of-function variants
should cause increased olfactory acuity as SCN9A loss-of-function
variants induce anosmia, was verified by inverse concluding that
the presence of wild-type genetics was associated with the opposite
effects, i.e., reduced pain perception and olfactory acuity. This way
we verified that there is a robust link between nociceptive and
olfactory acuities at Nav1.7 ion channel level [15] and that this link
works in both directions, rather than in the already known
negative direction of sensory function loss [2,5,6].
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insensitivity to pain due to SCN9A channelopathy [40] were
reported to be otherwise healthy except anosmia [2], pathophys-
iological implications of SCN9A are not limited to pain and
olfaction [41,42]. Gustation may be another sense affected by
functional changes in the Nav1.7 sodium channels. In particular,
SCN9A, together with SCN2A and SCN3A, was found in cells
expressing TRPM5, which is attributed to the initial sodium influx
in sweet, bitter, and umami taste cells [43]. There it is likely to
account for the tetrodotoxin-sensitive sodium currents [43].
Recently, a new SCN9A missense variant (G2567A leading to an
amino acid exchange from glycine to aspartic acid at position 856)
has been linked to abnormal limb development in three male
family members reporting erythema and burning pain in their
distal extremities [44]. Further associations have been shown with
the hereditary generalized epilepsy with febrile seizures [45] and
with other hereditary epilepsy phenotypes [45,46]. Outside the
nervous system, Nav1.7 plays a role in cell migration, endocytosis,
and secretion during progression of aortic intimal hyperplasia [47].
SCN9A is also expressed in human prostate cancer [48,49], for
which it has been proposed as a biomarker [50]. Thus, there are
plenty of other physiological systems and functions than pain and
olfaction that are likely to be affected by functional SCN9A
variants.
Neither are pathophysiological consequences associated with
SCN9A restricted to nociception and olfaction, nor is the link
between pain and smell perception restricted to SCN9A. Indeed,
these two evolutionarily ancient sensory systems [51,52] share
more common features on the molecular level. For example, the
cannabinoid system not only plays an important role in
nociception [53], but cannabinoids like 2-arachidonoyl-glycerol
are also synthesized in olfactory receptor neurons of Xenopus
laevis larvae. There, they control odor detection thresholds via
cannabinoid receptor activation [54]. Also transient receptor
potential cation channel, subfamily V, member 1, activated by
heat, protons and capsaicin are expressed at nociceptors, pain
relevant brain areas [55] and also in the olfactory bulb [56].
Odor thresholds have been reported to be unrelated to higher
cognitive factors, whereas proficiency in executive functioning and
semantic memory contributed significantly to odor discrimination
and identification performance [57]. Since only olfactory thresh-
olds were presently increased, while discrimination and identifi-
cation remained unaffected, this supports a more peripherally than
centrally localized effect of increased Nav1.7 function. The same
applies for the increased nociception. Only recently it has been
shown that small nerve fiber neuropathy is caused by the
expression of gain of function mutant sodium channels in small
diameter peripheral axons [58]. This would be consistent with the
reported predominant localization of Nav1.7 channels, which are
preferentially expressed within dorsal root ganglion neurons and
their small-diameter peripheral axons [59].
The present results establish olfactory effects as a class effect of
future Nav1.7 modulating analgesics [9,10]. Olfactory side effects
seem unavoidable, as opposed to other side effects, such as
cardiovascular side effects. The latter seem to be owed to an
insufficient specificity for Nav1.7, e.g. benzazepinones binding at
Nav1.5 [60] that is expressed on the cardiac muscle [61]. Although
this might be a disadvantage for future analgesics, when thinking
in the opposite direction, Nav1.7 activation may be suitable as a
cure for remnant olfactory function. However, at this point, this
assumption is purely speculative. This is amongst other things
because the exact mechanism of hyposmia, for instance, in patients
with post-viral olfactory loss or patients with sinunasal disease, is
often unclear. While olfactory receptor neurons (ORN) are still
present they appear to be deformed or some of their cilia may be
lost in post-viral olfactory loss [62], ORNs appear to be normal in
sinunasal disease and the olfactory disorder seems to originate
from functional changes at cellular level [63]. Even in patients with
posttraumatic olfactory loss it is uncertain whether shearing of the
olfactory fiber is the major contributor to olfactory loss [64] or
whether it results from actual brain damage. Moreover, the success
of a Nav1.7 activating drug as a cure for remnant olfactory
function will depend on its therapeutic range and its nociceptive
side effects. Achieved olfactory effects would have to be greater
than those presently observed. In fact, at least 5.5 points difference
in the composite TDI score are required for a perceived change of
olfactory function [31]. While systemic nociceptive side effects may
be avoided by a local intranasal administration, the possibility of
local painful side effects due to Nav1.7 activation on nociceptors
still exists. Taken together, the utility of Nav1.7 modulating agents
as a cure for olfactory disorders remains uncertain. Nevertheless, it
is worth assessing as there is a need for such drugs. Olfactory loss
Figure 1. Olfactory and pressure pain thresholds increased
with increasing number of wild-type SCN9A haplotype alleles
rs41268673C/rs6746030C. Please note that the olfactory threshold
to phenylethylethanol is scaled inversely as the ordinate indicates
dilution steps, with higher numbers denoting lower thresholds. Thus,
both sensory thresholds increase in the same direction indicating that
the presence of SCN9A variants lowers the thresholds making the
subject more sensitive against smell and pain stimuli. Single data and
the median (thick horizontal red line) are shown. Significant genotype
effects were also found when excluding group zero.
doi:10.1371/journal.pone.0068654.g001
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a reduction in the enjoyment of food [65], will impact the quality
of life and may greatly affect certain professionals who rely on their
sense of smell. Cures, on the other hand, are rare [66] and
restricted to a few agents with local decongestive or anti-
inflammatory actions such as metazolines [67] or corticosteroids
[68] and further substances such as the N-methyl-D-aspartic acid
antagonist caroverine [69] or the phosphodiesterase inhibitor
theophylline [70].
Present results verified the hypothesis that there is a link
between nociception and olfaction at Nav1.7 sodium channel level
in the gain-of-function direction, adding to the previously known
opposite effects of loss-of-function mutations in the SCN9A gene
and hence, establishing that the link is bidirectional. A wild-type
SCN9A haplotype composed of rs41268673C/rs6746030C alleles
was identified to be linked with a comparatively reduced pain
perception and olfaction acuity. This haplotype is frequent and
found in a random sample of Caucasians at an allelic frequency of
82.5%. It is one of the few human genetic variants modulating
olfactory function. However, as often seen with frequent genetic
variants [71], it confers only a small effect size resulting in a
measurable although not yet perceivable change in olfaction
without pathologic enhancement of nociception. From a pharma-
cological point of view, the results indicate that modulation of
Nav1.7 may serve different clinical purposes. This includes
deactivation for the treatment of pain but also activation as a
cure of diminished olfaction for which a medical need exists [66].
Nevertheless, pharmacological modulation of Nav1.7 function will
always be associated with nociceptive and olfactory effects in both
directions.
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